期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 126, 期 -, 页码 823-843出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2016.12.005
关键词
Alzheimer's disease; Amyloid-beta; Cholinesterase; Quinazoline; Molecular modeling
资金
- Faculty of Science, the School of Pharmacy, University of Waterloo
- Ontario Mental Health Foundation
- NSERC-Discovery [RGPIN: 03830-2014]
- Canada Foundation for Innovation, CFI-ELF
- Ontario Research Fund (ORF)
- Early Researcher Award, Ministry of Research and Innovation, Government of Ontario, Canada (PR)
A library of fifty-seven 2,4-disubstituted quinazoline derivatives were designed, synthesized and evaluated as a novel class of multi-targeting agents to treat Alzheimer's disease (AD). The biological assay results demonstrate the ability of several quinazoline derivatives to inhibit both acetyl and butyrylcholinesterase (AChE and BuChE) enzymes (IC50 range = 1.6-30.5 mu M), prevent beta-amyloid (A beta) aggregation (IC50 range 270 nM-16.7 mu M) and exhibit antioxidant properties (34-63.4% inhibition at 50 mu M). Compound 9 (N-2-(1-benzylpiperidin-4-yl)-N-4-(3,4-dimethoxybenzyl)quinazoline-2,4-diamine) was identified as a dual inhibitor of cholinesterases (AChE IC50 = 2.1 mu M); BuChE IC50 = 8.3 mu M) and exhibited good inhibition of A beta aggregation (A beta 40 IC50 = 2.3 mu M). Compound 15b (4-(benzylamino) quinazolin-2-ol) was the most potent A beta aggregation inhibitor (A beta 40 IC50 = 270 nM) and was similar to 4 and 1.4-fold more potent compared to the reference agents curcumin and resveratrol. These comprehensive structure activity-relationship (SAR) studies demonstrate the application of a 2,4-disubstituted quinazoline ring as a suitable template to develop multi-targeting agents to treat AD. Crown Copyright (C) 2016 Published by Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据